Neurol. praxi. 2026;27(1):34-39 | DOI: 10.36290/neu.2025.052

Carriers of dystrophinopathies - a neglected group of patients

MUDr. Hana Drašnarová, MUDr. Livie Mensová, MUDr. Radim Mazanec, Ph.D.
Neuromuskulární centrum ERN, Neurologická klinika 2. LF UK a FN Motol, Praha

Dytrophinopathies are X-linked genetic dysorders caused by Dystrophine gene mutation. The phenotypes of patients include the well-known forms of Duchenne and Becker muscular dystrophy, DMD-related dilated cardiomyopathy in men, but also less well-known and highly variable forms of dystrophinopathies in female carriers. The disease in women is most often caused by inactivation of chromosome X. It may be manifested as an isolated elevation of muscle enzymes tests, other female patients may suffer from severe muscle weakness, dilated cardiomyopathy or other extramuscular complications. The diagnostic method of choice is a molecular genetic examination of the dystrophin gene. There is no causal therapy available, therapy is limited to symptomatic treatment, prevention of complications and genetic counselling.

Keywords: muscular dystrophies, woman carriers of dystrophinopathy, cardiomyopathy.

Received: May 26, 2025; Revised: June 8, 2025; Accepted: June 10, 2025; Prepublished online: June 10, 2025; Published: March 11, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drašnarová H, Mensová L, Mazanec R. Carriers of dystrophinopathies - a neglected group of patients. Neurol. praxi. 2026;27(1):34-39. doi: 10.36290/neu.2025.052.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 11.3.2027

    References

    1. Adorisio R, Mencarelli E, Cantarutti N, et al. Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies. J Clin Med. 2020;9(10):3186. doi:10.3390/jcm9103186. Go to original source... Go to PubMed...
    2. Carraro L, Iosca A, Dainesi MI, et al. Cognitive function in DMD carriers: personal case series and literature review. PubMed. 2023;42(2-3):53-59. doi:10.36185/2532-1900-354. Go to original source...
    3. D'Anna M, Nelson JM, Ervasti JM. Dystrophin: A Multifaceted Protein Critical for Muscle Health. In: Jez J, ed. Encyclopedia of Biological Chemistry III. 3rd ed. Elsevier. 2021:625-638. doi:10.1016/B978-0-12-809633-8.21355-1. Go to original source...
    4. Demirci H, Durmus H, Toksoy G, et al. Cognition of the mothers of patients with Duchen-ne muscular dystrophy. Muscle Nerve. 2020;62(6):710-716. doi:10.1002/mus.27057. Go to original source... Go to PubMed...
    5. Duan D, Goemans N, Takeda S, et al. Duchenne muscular dystrophy. Nature Reviews Disease Primers. 2021;7(1). doi:10.1038/s41572-021-00248-3 Go to original source... Go to PubMed...
    6. Hoogerwaard E, Bakker E, Ippel P, et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in the Netherlands: a cohort study. The Lancet. 1999;353(9170):2116-2119. doi:10.1016/s0140-6736(98)10028-4 Go to original source... Go to PubMed...
    7. Hoogerwaard EM, Van Der Wouw PA, Wilde AAM, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscular Disorders. 1999;9(5):347-351. doi:10.1016/s0960-8966(99)00018-8. Go to original source... Go to PubMed...
    8. Houwen-van Opstal SLS, Tak RO, van den Heuvel FMA, et al. Long-term outcomes for females with early-onset dystrophinopathy. Dev Med Child Neurol. 2023;65(8):979-988. doi:10.1111/dmcn.15496. Go to original source... Go to PubMed...
    9. Ishizaki M, Kobayashi M, Adachi K, et al. Female dystrophinopathy: Review of current literature. Neuromuscul Disord. 2018;28(7):572-581. doi:10.1016/j.nmd.2018.04.005. Go to original source...
    10. Kaczorowska E, Chrzanowska K, Smyk M, et al. Co-incidence of Turner syndrome and Duchenne muscular dystrophy - an important problem for the clinician. Dev Period Med. 2016;20(4):343-346.
    11. Keil ES, Schulze ML, Kitzberger I, et al. Clinical spectrum of manifestations in symptomatic female with Duchenne muscular dystrophy: A concise review. Translational Science of Rare Diseases. 2023;6(4):117-122. doi:10.3233/TRD-220056. Go to original source...
    12. Lee BH. The Dystrophinopathies. Muscle and Neuromuscular Junction Disorders. 2022;28(6):1678-1697. doi:10.1212/CON.0000000000001208. Go to original source... Go to PubMed...
    13. Lim KRQ, Sheri N, Nguyen Q, et al. Cardiac Involvement in Dystrophin-Deficient Females: Current Understanding and Implications for the Treatment of Dystrophinopathies. Genes (Basel). 2020;11(7):765. doi:10.3390/genes11070765. Go to original source... Go to PubMed...
    14. Magliano L, Patalano M, Sagliocchi A, et al. Burden, professional support, and social network in families of children and young adults with muscular dystrophies. Muscle Nerve. 2015;52(1):13-21. doi:10.1002/mus.24503. Go to original source... Go to PubMed...
    15. Percy ME, Chang LS, Murphy EG, et al. Serum creatine kinase and pyruvate kinase in duchenne muscular dystrophy carrier detection. Muscle & Nerve. 1979;2(5):329-339. doi:10.1002/mus.880020503. Go to original source... Go to PubMed...
    16. Silva THD, Anequini IP, Fávero FM, et al. Functional performance and muscular strength in symptomatic female carriers of Duchenne muscular dystrophy. Arq Neu-ropsiquiatr. 2020;78(3):143-148. doi:10.1590/0004-282X20190168. Go to original source... Go to PubMed...
    17. Standardy péče o pacienty s Duchennovou svalovou dystrofií [Cit. 4.5.2025]. Avai-lable from: https://www.parentproject.cz/files/dmd-standardy-fin-nahled.pdf.
    18. Tetorou K, Aghaeipour A, Singh S, et al. The role of dystrophin isoforms and intera-ctors in the brain. Brain. 2024;awae384. doi:10.1093/brain/awae384. Go to original source... Go to PubMed...
    19. Vaillend C, Aoki Y, Mercuri E, et al. Duchenne muscular dystrophy: Recent insights in brain-related comorbidities. Nat Commun. 2025;16:1298. doi:10.1038/s41467-025-56644-w. Go to original source... Go to PubMed...
    20. Verebi C, Gravrand V, Bienvenu T, et al. A retrospective cohort study and review of the literature about germline mosaicism in Duchenne/Becker muscular dystrophy prenatal counseling: How to estimate the recurrence risk in clinical settings? J Genet Couns. Pu-blished online June 19, 2024. doi:10.1002/jgc4.1932. Go to original source... Go to PubMed...
    21. Yazaki M, Yoshida K, Nakamura A, et al. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol. 1999;42(3):145-149. doi:10.1159/000008089. Go to original source... Go to PubMed...
    22. Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health. 2015;51(8):759-764. doi:10.1111/jpc.12868. Go to original source... Go to PubMed...
    23. Zhong J, Xie Y, Bhandari V, et al. Clinical and genetic characteristics of female dystrophinopathy carriers. Mol Med Rep. 2019;19(4):3035-3044. doi:10.3892/mmr.2019.9982. Go to original source... Go to PubMed...
    24. Zimowski JG, Pilch J, Pawelec M, et al. A rare subclinical or mild type of Becker muscular dystrophy caused by a single exon 48 deletion of the dystrophin gene. J Appl Ge-net. 2017;58(3):343-347. doi:10.1007/s13353-017-0391-8. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.